ReviewPharmaceutics2020
Antibodies for the Treatment of Brain Metastases, a Dream or a Reality?
Review in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Molecular determinants for brain targeting by peptides: a meta-analysis approach with experimental validation.Fluids and barriers of the CNS · 2024Pooled it
- Chimeric peptide-based radiopharmaceuticals for glioblastoma imaging and therapy by targeting mHsp70 and enhancing BBB penetration.Chemical science · 2026Article
- Glycerol-mediated nose-to-brain codelivery of anti-IL-17 and anti-CD73 antibodies enhances immunotherapy for melanoma brain metastases.Science advances · 2026Article
- Amivantamab Monotherapy for Lung Adenocarcinoma With Leptomeningeal Seeding: A Case Report.Respirology case reports · 2026Article
- Central nervous system involvement in plasma cell neoplasms: a rare presentation illustrated by three cases.International journal of hematology · 2026Article
- Therapeutic potential of plant-derived exosome-like nanoparticles for CNS diseases: advancements in preparation and characterization.Annals of medicine · 2025Review
- Review
- Discovery of a Small Molecule TREM2 Agonist with Improved In Vitro Pharmacokinetic Profile and Validated Target Engagement.ACS medicinal chemistry letters · 2025Article
- Article
- Systemic HER3 ligand-mimicking nanobioparticles enter the brain and reduce intracranial tumour growth.Nature nanotechnology · 2025Article
- A Site-Specific MiniAp4-Trastuzumab Conjugate Prevents Brain Metastasis.Molecular pharmaceutics · 2025Article
- A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases.Experimental hematology & oncology · 2024Article
- A Combination of Magnoflorine and Spinosin Improves the Antidepressant effects on CUMS Mouse Model.Current drug metabolism · 2024Article
- Enhancing Antibody Exposure in the Central Nervous System: Mechanisms of Uptake, Clearance, and Strategies for Improved Brain Delivery.Journal of nanotheranostics · 2023Article
- A Promising Approach: Magnetic Nanosystems for Alzheimer's Disease Theranostics.Pharmaceutics · 2023Review
- Isolated relapse of plasma cell leukemia in the central nervous systems: a case report and literature review.International journal of hematology · 2023Review
- Targeting the Brain with Single-Domain Antibodies: Greater Potential Than Stated So Far?International journal of molecular sciences · 2023Review
- Pretargeted Imaging beyond the Blood-Brain Barrier-Utopia or Feasible?Pharmaceuticals (Basel, Switzerland) · 2022Article
- Development of CAR T Cell Therapy in Children-A Comprehensive Overview.Journal of clinical medicine · 2022Review
- Current Chemical, Biological, and Physiological Views in the Development of Successful Brain-Targeted Pharmaceutics.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The incidence of brain metastases (BM) in cancer patients is increasing. After diagnosis, overall survival (OS) is poor, elicited by the lack of an effective treatment. Monoclonal antibody (mAb)-based therapy has achieved remarkable success in treating both hematologic and non-central-nervous system (CNS) tumors due to their inherent targeting specificity. However, the use of mAbs in the treatment of CNS tumors is restricted by the blood-brain barrier (BBB) that hinders the delivery of either small-molecules drugs (sMDs) or therapeutic proteins (TPs). To overcome this limitation, active research is focused on the development of strategies to deliver TPs and increase their concentration in the brain. Yet, their molecular weight and hydrophilic nature turn this task into a challenge. The use of BBB peptide shuttles is an elegant strategy. They explore either receptor-mediated transcytosis (RMT) or adsorptive-mediated transcytosis (AMT) to cross the BBB. The latter is preferable since it avoids enzymatic degradation, receptor saturation, and competition with natural receptor substrates, which reduces adverse events. Therefore, the combination of mAbs properties (e.g., selectivity and long half-life) with BBB peptide shuttles (e.g., BBB translocation and delivery into the brain) turns the therapeutic conjugate in a valid approach to safely overcome the BBB and efficiently eliminate metastatic brain cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.